Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19950132 | 0.92 | MAP4K1 (0.74) | MAP4K1FGFR1FGFR2KDRKIT | |
| SCHEMBL19965540 | 0.90 | MAP4K1 (0.61) | MAP4K1FGFR1FGFR2KDRKIT | |
| SCHEMBL30069701 | 0.90 | FGFR1 (0.69) | MAP4K1FGFR1FGFR2KITFLT3 | |
| SCHEMBL19950000 | 0.90 | FGFR1 (0.69) | MAP4K1FGFR1FGFR2KITFLT3 | |
| SCHEMBL19950660 | 0.90 | MAP4K1 (0.62) | MAP4K1FGFR1FGFR2KDRKIT | |
| SCHEMBL19950406 | 0.90 | MAP4K1 (0.62) | MAP4K1FGFR1FGFR2KDRKIT | |
| SCHEMBL30069685 | 0.90 | MAP4K1 (0.62) | MAP4K1FGFR1FGFR2KDRKIT | |
| SCHEMBL19950074 | 0.90 | MAP4K1 (0.62) | MAP4K1FGFR1FGFR2KDRKIT | |
| SCHEMBL29746704 | 0.90 | MAP4K1 (0.62) | MAP4K1FGFR1FGFR2KDRKIT | |
| SCHEMBL31672292 | 0.89 | MAP4K1 (0.61) | MAP4K1FGFR1FGFR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | HIPK1, MCL1, HYPK | MAP4K1 103/4885FGFR1 437/4885FGFR2 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.